Literature DB >> 30845376

The synthetic cathinone psychostimulant α-PPP antagonizes serotonin 5-HT2A receptors: In vitro and in vivo evidence.

Yiming Chen1, Bruce E Blough2, Kevin S Murnane1, Clinton E Canal1.   

Abstract

Synthetic cathinones (SCs) are β-keto analogs of amphetamines. Like amphetamines, SCs target monoamine transporters; however, unusual neuropsychiatric symptoms have been associated with abuse of some SCs, suggesting SCs might possess additional pharmacological properties. We performed radioligand competition binding assays to assess the affinities of nine SCs at human 5-HT2A receptors (5-HT2A R) and muscarinic M1 receptors (M1 R) transiently expressed in HEK293 cells. None of the SCs exhibited affinity at M1 R (minimal displacement of [~Kd ] [3 H]scopolamine up to 10 μM). However, two SCs, α-pyrrolidinopropiophenone (α-PPP) and 4-methyl-α-PPP, had low μM Ki values at 5-HT2A R. In 5-HT2A R-phosphoinositide hydrolysis assays, α-PPP and 4-methyl-α-PPP displayed inverse agonist activity. We further assessed the 5-HT2A R functional activity of α-PPP, and observed it competitively antagonized 5-HT2A R signaling stimulated by the 5-HT2 R agonist (±)-2,5-dimethoxy-4-iodoamphetamine (DOI; Kb  = 851 nM). To assess in vivo 5-HT2A R activity, we examined the effects of α-PPP on the DOI-elicited head-twitch response (HTR) in mice. α-PPP dose-dependently blocked the HTR with maximal suppression at 10 mg/kg (P < 0.0001), which is a moderate dose used in studies investigating psychostimulant properties of α-PPP. To corroborate a 5-HT2A R mechanism, we also tested 3,4-methylenedioxy-α-PPP (MDPPP) and 3-bromomethcathinone (3-BMC), SCs that we observed had 5-HT2A R Ki s > 10 μM. Neither MDPPP nor 3-BMC, at 10 mg/kg doses, attenuated the DOI HTR. Our results suggest α-PPP has antagonist interactions at 5-HT2A R in vitro that may translate at physiologically-relevant doses in vivo. Considering 5-HT2A R antagonism has been shown to mitigate effects of psychostimulants, this property may contribute to α-PPPs unpopularity compared to other monoamine transporter inhibitors.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  2,5-dimethoxy-4-iodoamphetamine (DOI); 5-HT2A; cathinone; psychostimulant; α-pyrrolidinopropiophenone (α-PPP)

Mesh:

Substances:

Year:  2019        PMID: 30845376      PMCID: PMC6615953          DOI: 10.1002/dta.2582

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  70 in total

1.  Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding.

Authors:  Paul J Fletcher; Andrew J Grottick; Guy A Higgins
Journal:  Neuropsychopharmacology       Date:  2002-10       Impact factor: 7.853

2.  Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems.

Authors:  J Maj; Z Rogóz
Journal:  J Neural Transm (Vienna)       Date:  1999       Impact factor: 3.575

3.  Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry.

Authors:  Dietmar Springer; Giselher Fritschi; Hans H Maurer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-11-05       Impact factor: 3.205

4.  Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats.

Authors:  L R McMahon; K A Cunningham
Journal:  J Pharmacol Exp Ther       Date:  2001-04       Impact factor: 4.030

5.  The prevalence of psychotic symptoms among methamphetamine users.

Authors:  Rebecca McKetin; Jennifer McLaren; Dan I Lubman; Leanne Hides
Journal:  Addiction       Date:  2006-10       Impact factor: 6.526

6.  S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.

Authors:  M J Millan; A Gobert; F Lejeune; A Newman-Tancredi; J M Rivet; A Auclair; J L Peglion
Journal:  J Pharmacol Exp Ther       Date:  2001-08       Impact factor: 4.030

7.  Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs.

Authors:  S Wee; K G Anderson; M H Baumann; R B Rothman; B E Blough; W L Woolverton
Journal:  J Pharmacol Exp Ther       Date:  2005-01-26       Impact factor: 4.030

8.  5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB.

Authors:  M F O'Neill; C L Heron-Maxwell; G Shaw
Journal:  Pharmacol Biochem Behav       Date:  1999-06       Impact factor: 3.533

Review 9.  Nonhuman primate neuroimaging and the neurobiology of psychostimulant addiction.

Authors:  Leonard L Howell; Kevin S Murnane
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

10.  Inhibition of transport function and desipramine binding at the human noradrenaline transporter by N-ethylmaleimide and protection by substrate analogs.

Authors:  Kevin F Foley; Nicholas V Cozzi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-04-18       Impact factor: 3.000

View more
  4 in total

1.  Structure-Activity Relationship Study of Psychostimulant Synthetic Cathinones Reveals Nanomolar Antagonist Potency of α-Pyrrolidinohexiophenone at Human Muscarinic M2 Receptors.

Authors:  Yiming Chen; Clinton E Canal
Journal:  ACS Chem Neurosci       Date:  2020-03-03       Impact factor: 4.418

Review 2.  Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications.

Authors:  Arianna Giorgetti; Jennifer P Pascali; Paolo Fais; Guido Pelletti; Andrea Gabbin; Giorgia Franchetti; Giovanni Cecchetto; Guido Viel
Journal:  Life (Basel)       Date:  2021-05-14

3.  Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice.

Authors:  Tanishka S Saraf; Daniel E Felsing; Jessica L Armstrong; Raymond G Booth; Clinton E Canal
Journal:  Epilepsy Res       Date:  2021-05-27       Impact factor: 2.991

4.  Reinforcing Effects of the Synthetic Cathinone α-Pyrrolidinopropiophenone (α-PPP) in a Repeated Extended Access Binge Paradigm.

Authors:  Erin K Nagy; Paula F Overby; M Foster Olive
Journal:  Front Psychiatry       Date:  2020-08-25       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.